Idrentifying the Risk of Colorectal Cancer Recurrence
Approximately 28% of all resected colorectal cancer tumours are classified as Stage II disease. From here, it’s hard to predict which patients will suffer a recurrence after surgery.
Despite this, many patients are routinely started on 5FU/capecitabine therapy. Studies suggest that use of adjuvant 5FU therapy in Stage II or IIIa CRC patients would only increase survival by 3-5% and a large proportion of these patients would suffer severe side effects from 5FU treatment. There is even a 0.5-1% risk of treatment-associated death.
Identifying patients at low, intermediate and high risk of colorectal cancer relapse has been a major objective of OCB. A wrong or inaccurate prognosis can have devastating consequences for the patient.
OncoProg uses innovative digital pathology with proprietary algorithms to create an informative risk profile for patients that allows  a treatment decision based on prognostic understanding.
Identify risk of relapse before it happens
Using digital pathology to examine resected tumour tissue with our proprietary DNA ploidy and stroma content, we combine these biomarkers to create a reliable risk profile for each patient.
This innovative technology helps you make an informed clinical decision following surgery, whether this is a better-targeted adjuvant chemotherapy for high-risk patients or avoiding chemotherapy altogether in patients who have a high likelihood of cure by surgery alone.
OncoProg has been clinically validated in approximately 1,000 Stage II colorectal cancer patients and around 2,500 patients in total. So you can be confident in making the right choice for every patient.
Quasar 2 Study
The QUASAR 2 study, along with additional data from Oslo University Hospital, Aker (Norway) and the Gloucester Colorectal Cancer Study were used to validate the use of tumour ploidy and stroma when stratifying patients into clinically useful groups based on their risk of cancer specific survival.
The results categorised patients into three clinically meaningful groups:
low-, intermediate- and high-risk of cancer recurrence or cancer-related death, allowing clinicians to better target specific patients with adjuvant chemotherapy after surgery.
News & Press
Oxford Cancer Biomarkers announces first patient into its clinical study for its precision oncology OncoProg test for colorectal cancer
PRESS RELEASE: OncoHelix and Oxford Cancer Biomarkers Enter into a Partnership to Offer Breakthrough Cancer Genetic Screening Test to Canadians
Our Other Products
Identifies healthy individuals with a 5 fold higher risk of developing colorectal cancer
What if you could find out which of your patients are at low, intermediate or high risk of colorectal cancer relapse?
OncoProg uses innovative AI and gene analysis to create a risk profile for your patients and help inform your next clinical decision.
Reduces risk of chemotherapy toxicity
Identifies whether your patient is at risk of capecitabine toxicity. Enables a clinically rotreatment decisions and reduces the risk of severe adverse effects with ToxNav.
Improve your patients’ quality of life and reduce treatment costs. Proven to be clinically effective.